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Abstract
The human minor Histocompatibility Antigen HMHA-1 is a major target of immune responses after allogeneic stem cell
transplantation applied for the treatment of leukemia and solid tumors. The restriction of its expression to hematopoietic
cells and many solid tumors raised questions regarding its cellular functions. Sequence analysis of the HMHA-1 encoding
HMHA1 protein revealed the presence of a possible C-terminal RhoGTPase Activating Protein (GAP) domain and an N-
terminal BAR domain. Rho-family GTPases, including Rac1, Cdc42, and RhoA are key regulators of the actin cytoskeleton and
control cell spreading and migration. RhoGTPase activity is under tight control as aberrant signaling can lead to pathology,
including inflammation and cancer. Whereas Guanine nucleotide Exchange Factors (GEFs) mediate the exchange of GDP for
GTP resulting in RhoGTPase activation, GAPs catalyze the low intrinsic GTPase activity of active RhoGTPases, resulting in
inactivation. Here we identify the HMHA1 protein as a novel RhoGAP. We show that HMHA1 constructs, lacking the N-
terminal region, negatively regulate the actin cytoskeleton as well as cell spreading. Furthermore, we show that HMHA1
regulates RhoGTPase activity in vitro and in vivo. Finally, we demonstrate that the HMHA1 N-terminal BAR domain is auto-
inhibitory as HMHA1 mutants lacking this region, but not full-length HMHA1, showed GAP activity towards RhoGTPases. In
conclusion, this study shows that HMHA1 acts as a RhoGAP to regulate GTPase activity, cytoskeletal remodeling and cell
spreading, which are crucial functions in normal hematopoietic and cancer cells.
Citation: de Kreuk B-J, Schaefer A, Anthony EC, Tol S, Fernandez-Borja M, et al. (2013) The Human Minor Histocompatibility Antigen1 Is a RhoGAP. PLoS ONE 8(9):
e73962. doi:10.1371/journal.pone.0073962
Editor: Steen Henning Hansen, Children’s Hospital Boston, United States of America
Received July 5, 2013; Accepted July 24, 2013; Published September 23, 2013
Copyright:  2013 de Kreuk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: BJDK was supported by LSBR (Landsteiner Foundation for Blood Transfusion Research) grant 0731. AS was supported by LSBR grant 0903. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: p.hordijk@sanquin.nl
Introduction
Human minor Histocompatibility (H) antigens are important
immunological barriers after allogeneic stem cell transplantation
(SCT) applied for the treatment of leukemia and solid tumors.
Minor H antigens are HLA-restricted peptides generated from
specific intracellular polymorphic proteins. Upon presentation of
these peptides on the cell surface, minor H antigens can stimulate
cytotoxic T cells (CTLs) targeting these epitopes [1]. HMHA-1
was the first autosomal minor H antigen identified and is the most
studied minor H antigen to date [2]. HMHA-1 CTLs can be
detected frequently after allogeneic SCT coinciding with the Graft
versus Leukemia effect [3]. HMHA-1 gene expression is restricted
to the hematopoietic system, comprising normal and leukemic
cells, including progenitor cells [4]. Although absent in normal
epithelial cells, HMHA-1 gene expression is also observed in
epithelial tumors of many different entities [5], suggesting a role of
HMHA-1 in carcinogenesis [6]. Indeed, HMHA-1 CTLs eradi-
cate human leukemia and solid tumors in immunosuppressed mice
[7,8]. The apparent relevance of HMHA-1 as antigen in the
context of allogeneic SCT, the restriction of its expression to
hematopoietic cells and its aberrant expression in solid tumors
raised questions regarding its cellular functions.
Sequence analysis of the HMHA-1 encoding HMHA1 protein
revealed the presence of a possible C-terminal RhoGTPase
Activating Protein (GAP) domain and an N-terminal Bin/
Amphiphysin/Rvs (BAR) domain [6]. Rho-family GTPases and
in particular Rac1, Cdc42, and RhoA are key regulators of the
actin cytoskeleton, which is dynamically remodeled during cell
adhesion, spreading and migration [9]. These GTPases control
cell morphology, polarity, cell adhesion and directional motility by
regulating the formation of filopodia, lamellipodia, stress fibers,
and focal adhesions in a tightly controlled fashion [10,11]. When
RhoGTPases are in their active, GTP-bound state, downstream
effectors, such as the p21-activated kinase (PAK) serine/threonine
kinase for Rac1, or Rho-associated coiled-coil-containing protein
kinase (ROCK) [12] for RhoA, are activated to regulate
downstream signaling.
Both activation and inactivation of RhoGTPases is under tight
control. In response to extracellular stimuli, GEFs control the
exchange of GDP for GTP, activating the GTPases [13].
Conversely, GAPs regulate the hydrolysis of GTP to GDP by
catalyzing the low intrinsic GTPase activity, thereby inactivating
the GTPase [14]. Finally, whereas most active RhoGTPases are
associated to the inner leaflet of the plasma membrane, inactive
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RhoGTPases reside in the cytoplasm bound to the Rho guanine
nucleotide dissociation inhibitor (RhoGDI) [15].
BAR domains are modules involved in membrane dynamics
including endocytosis and vesicle transport [16,17]. Many BAR
domain-containing proteins have been shown to regulate RhoGT-
Pase activity and function [18]. One subclass of these, including
SH3BP1, Oligophrenin-1 (OPHN1), and GRAF1, [19–21] bear
structural similarity to HMHA1 in that they encode both a BAR-
as well as a GAP-domain. As the cellular role of HMHA-1
encoding HMHA1 protein is unknown we decided to investigate
the biological function of HMHA1.
We show that ectopic expression of HMHA1 mutants lacking
the N-terminal BAR domain but encoding the GAP domain
dramatically alters the organization of the F-actin cytoskeleton.
This is apparent from an overall loss of F-Actin as well as of focal
adhesions which is accompanied by strongly impaired cell
adhesion and spreading. We also show that HMHA1 interacts
and colocalizes with different RhoGTPases. Both in vitro and in vivo
studies showed that HMHA1 regulates RhoGTPase activity.
Finally, we demonstrate that the HMHA1 BAR domain auto-
inhibits its GAP function. In summary, our data identify HMHA1
as a novel RhoGAP which regulates actin dynamics and cell
spreading.
Materials and Methods
Antibodies, Reagents, and Expression constructs
Antibodies. Anti-Actin (A3853), anti-a-Tubulin (T6199),
anti-HA (H3663), and anti-HMHA1 (HPA019816) were from
Sigma. Anti-c-myc (13–2500) was from Invitrogen. Anti-Paxillin
(610620) was from Transduction Laboratories. For immunofluo-
rescence, anti-Rac1 (05–389) was from Millipore, and for Western
blot anti-Rac1 (610651) was from Transduction Laboratories.
Secondary HRP-labelled antibodies for Western blot were from
Pierce. Secondary Alexa-labelled antibodies for immunofluores-
cence were from Invitrogen. F-Actin was detected using Bodipy
650/665- Texas-Red- or Alexa-633-labelled Phalloidin (Invitro-
gen).
Expression constructs. To generate myc-tagged HMHA1
deletion constructs, pcDNA-2x-myc-HMHA1 was used as a
template for PCR. The following primers were used: For myc-
HMHA1 N-term, forward primer 59-GAGATCGATAT-
CAAGCTTTTCTCCAGGAAGAAACGAG-39 and reverse
primer 59-GAGATCTCTAGAGGATCCTCAGGCCGCCTT-
GGACAGC-39. For myc-HMHA1 C1-GAPtail, forward primer,
59-GAGATCGATATCAAGCTTTTCCGCCACGAGGGGC-39
and reverse primer 59-GAGATCTCTAGAGGATCCTCACAC-
GAATTCCGGCTGCC-39. For myc-HMHA1 C1-GAP, forward
primer 59-GAGATCGATATCAAGCTTTTCCGCCACGAGG-
GGC-39 and reverse primer 59-GAGATCTCTAGAGGATCCT-
CAGCCGTAGTGGACGATG-39. For myc-HMHA1 GAPtail,
forward primer 59-GAGATCGATATCAAGCTTCAGCTG-
TTCGGCCAGG-39 and reverse primer 59-GAGATCTCTA-
GAGGATCCTCACACGAATTCCGGCTGCC-39. For myc-
HMHA1 GAP, forward primer 59-GAGATCGATATCAAG-
CTTCAGCTGTTCGGCCAGG-39, and reverse primer 59-
GAGATCTCTAGAGGATCCTCAGCCGTAGTGGACGATG-
39. The products were cloned into a pcDNA-2x-myc vector. To
generate GST-HMHA1 constructs, pcDNA-2x-myc-HMHA1 was
used as a template for PCR. The following primers were used: For
GST-HMHA1 FL, forward primer 59-GAGATCGGATCCT-
TCTCCAGGAAGAAACGAG-39 and reverse primer 59-GA-
GATCTCTAGAGGATCCTCACACGAATTCCGGCTGCC-39.
For GST-HMHA1 N-term, forward primer 59-GAGATCG-
GATCCTTCTCCAGGAAGAAACGAG-39 and reverse primer
59-GAGATCGCGGCCGCTCAGGCCGCCTTGGACAGC-39.
For GST-HMHA1 C1-GAPtail, forward primer 59-GAGATCG-
GATCCTTCCGCCACGAGGGGC-39 and reverse primer 59-
GAGATCTCTAGAGGATCCTCACACGAATTCCGGCTG-
CC-39. The product was cloned into pGex-6p-1. All fusion
constructs were confirmed by sequencing. pmCherry(C1) was
from Clontech Laboratories. mCherry-Rac1 Q61L and G12V
were described previously (De Kreuk et al., 2011). HA-tagged
RhoA V14 and Cdc42 G12V were purchased from Missouri S&T
cDNA Rescource Center. GST-Rac1 WT was described previ-
ously [22]. GST-Rac1DC and GST-RhoADC were a kind gift
from A. Wittinghofer (Max-Planck Institute for Molecular
Physiology, Dortmund, Germany).
Lentiviral shRNAi and siRNA silencing
Lentiviral shRNA constructs for HMHA1 from the TRC/
Sigma Mission library were obtained from Sigma-Aldrich (St.
Louis, MI, USA). Scrambled shRNA (SHC002; Sigma-Aldrich)
was used as a negative control. Lentiviral particles expressing
shRNA constructs were prepared using HEK293T cells and virus
was transduced as described previously [23].
SDS-PAGE and Western blot analysis
Proteins were separated on SDS-PAGE gels followed by transfer
onto nitrocellulose transfer membrane using the iBlot Dry Blotting
System (Invitrogen) according to the manufacturers’ recommen-
dations. After blotting, membranes were blocked in 5% low fat
milk in TBST (Tris-Buffered Saline Tween-20) for 30 minutes and
subsequently the blots were incubated with the primary antibody
overnight at 4uC. Next, the blots were washed 3 times for 30
minutes in TBST and subsequently incubated with HRP-
conjugated secondary antibodies in TBST for 1 hour at RT.
Finally, blots were washed 3 times with TBST for 30 minutes each.
Blots were developed by ECL (GE Healthcare, Hoevelaken, The
Netherlands).
Confocal Laser Scanning Microscopy and FACS analysis
Twenty-four hours after cells were seeded on fibronectin-coated
glass coverslips, the indicated plasmids were transfected. After
24 hours, cells were fixed by 3.7% formaldehyde (Merck) in PBS
(10 minutes; RT) followed by permeabilization with 0.5% Triton
X-100 in PBS (5 minutes; RT). Coverslips were then incubated for
15 minutes with 2% BSA in PBS at 37uC to prevent aspecific
binding. Immunostainings were performed with the indicated
antibodies (60 minutes; RT). Fluorescent imaging was performed
with a confocal laser scanning microscope (LSM510/Meta; Carl
Zeiss MicroImaging, Inc.) using a 63X/NA 1.40 (Carl Zeiss
MicroImaging, Inc.). Image acquisition was performed with Zen
2009 software (Carl Zeiss MicroImaging, Inc.). Image analysis for
quantification of paxillin staining was further performed using
Image J. Here, the average pixel intensity of paxillin staining, after
background subtraction and correction for surface area, was
calculated for 10–20 cells per condition. The mean +/2 SD was
calculated and statistical differences were determined using a
students’ t-test.
For FACS and image analysis using the Image Stream
technology (Amnis), Jurkat T cells were treated or not with
100 ng/ml CXCL12 (300-28A, Peprotech) for the indicated time-
points, fixed and permeabilized using Intraprep fix and perm
(IM2388, Beckman Coulter). Cells were subsequently stained for
HMHA1 and Rac1 and for F-actin using Bodipy-labelled
phalloidin. Image Stream analysis software was used for processing
of the data.
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Cell culture and transfections
Jurkat and HeLa cells were maintained at 37uC and 5% CO2 in
Iscove’s Modified Dulbecco’s Medium (IMDM; Biowhittaker)
suplemented with 10% heat-inactivated Fetal Calf Serum (Life
Technologies, Breda, The Netherlands), 300 mg/ml glutamine,
100 units/ml penicillin and streptomycin. HeLa cells were
transiently transfected with TransIT (Mirus) according to the
manufacturers’ recommendations.
GST Pull-Down Assays
For studying the direct interaction of HMHA1 with Rac1 or
RhoA, GST-fusion proteins were purified from BL21 bacteria as
described previously [22]. GST-HMHA1 was cut with precision
protease (GE Healthcare) overnight at 4uC while rotating. Next,
supernatant, containing purified HMHA1 without GST-tag and
beads, was harvested and used for the interaction studies or in vitro
GAP assay. GST-Rac1 and RhoA were allowed to bind GDP or
GppNHP overnight at 4uC while rotating. Binding of HMHA1 to
the RhoGTPases was assayed by Western blot analysis using the
anti-HMHA1 antibody.
RhoGTPase activity assays
Rac1 activation in HeLa or Jurkat cells, transfected/transduced
as indicated, was analyzed by a CRIB-peptide pull-down approach
as described previously [22]. Cells were lysed in NP-40 lysis buffer
(50 mM TRIS/HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2, 10%
glycerol and 1% NP40) supplemented with protease inhibitors
(Complete mini EDTA, Roche). Subsequently, lysates were
centrifuged at 20.000 xg for 10 minutes at 4uC. The supernatant
was then incubated with 30 mg of Pak1-CRIB peptide and
incubated at 4uC for 1 hour while rotating. Bound Rac1GTP
levels were detected by Western blot analysis.
Levels of RhoAGTP were measured using a RhoA G-Lisa kit
(BK124; Cytoskeleton) according to the manufacturers’ recom-
mendations.
In vitro GAP activity of HMHA1 was measured using a
RhoGAP Assay (BK105; Cytoskeleton) according to the manu-
facturers’ recommendations. In short, purified HMHA1 protein
(see above) was incubated together with the small GTPases, Rac1,
Cdc42, RhoA, and Ras in the presence of GTP (20 minutes;
37uC). Free inorganic phosphate (generated by the hydrolysis of
GTP to GDP) was detected by CytoPhos and subsequently
absorbance (650 nm) was measured. We used GTPase or GAP
protein only as a negative control and as a measure for the
intrinsic hydrolysis rate. p50RhoGAP was used as a positive
control for the assay.
Electric resistance measurements
For ECIS-based cell spreading experiments, golden ECIS
electrodes (8W10E; Applied Biophysics) were treated with
10 mM L-cysteine for 15 minutes. Subsequently electrodes were
coated with 10 mg/ml fibronectin in 0.9% NaCl for 1 hour at
37uC. Next, HeLa cells, transfected as indicated, were seeded at a
concentration of 100.000 cells per well in 400 ml IMDM with 10%
FCS. Impedance was measured continuously at 45 kHz using
ECIS model 9600. The increase in impedance, as a measure of cell
spreading [24], was recorded for one hour.
Homology Modeling
The homology model of the HMHA1 RhoGAP domain was
calculated by submitting the sequence of the human HMHA1
RhoGAP domain (residues 753–973) to the Phyre protein
structure prediction server which includes sequence alignments
with several RhoGAPs [25]. Superimpositions and figures were
prepared with PyMOL (PyMOL Molecular Graphics System,
Schroedinger, LLC).
Results
HMHA1 regulates the actin cytoskeleton and cell
spreading
Analysis of the HMHA1 protein sequence shows that it encodes
an N-terminal BAR domain followed by a C1 domain and a
RhoGAP domain. The C-terminal portion of the protein consists
of a proline-rich region as well as a PDZ-binding domain
(Figure 1A). Interestingly, similar to HMHA1, other BAR domain
proteins such as OPHN1 and GRAF1, also encode a RhoGAP
domain [18] and are involved in regulating the actin cytoskeleton.
We therefore investigated the role of HMHA1 in RhoGTPase
signaling and actin remodeling.
We generated immunotagged full-length and deletion constructs
of HMHA1 (Figure 1A). Because in several BAR-GAP proteins
the BAR domain autoinhibits GAP function [26], both an N-
terminal BAR-domain-containing construct and C-terminal con-
structs including the RhoGAP domain were generated (Figure 1A).
In addition to its hematopoietic specific expression (10), the
HMHA1 gene is also expressed in epithelial tumor cells [5]. This
interesting dual expression challenged us to visualize HMHA1
cellular protein distribution and dynamics. Hereto, different
HMHA1 constructs were expressed in HeLa cells that do not
express HMHA1 endogenously. We found no effects of full-length
HMHA1 (FL) or the N-terminal construct (N-term) on overall
morphology of HeLa cells (Figure 1B, upper three rows).
Interestingly, cells expressing the C1-GAP, the C1-GAPtail and
the GAPtail proteins show reduced membrane ruffling and
extensive formation of cellular spines. Additionally, these cells
show reduced cell spreading (Figure 1B). Our results also show
that the GAP domain of HMHA1 induces a significant change in
cell shape. The finding that FL HMHA1 does not induce this
phenotype, is suggestive for a negative regulatory role of the BAR
domain.
Full-length (FL) HMHA1 localized to the cytoplasm as well as to
membrane ruffles (Figure 2). A similar distribution was found for
the N-terminal (N-term) construct, encoding the BAR domain.
Interestingly, a fraction of HMHA1-N-term localizes to tubular
structures (Figure 2) known to be formed by the membrane-
deforming activity of BAR domains. The HMHA1 C1-GAPtail or
GAPtail proteins show primarily a diffuse cytoplasmic distribution
with a small fraction detectable on the plasma membrane
(Figure 2). Interestingly, expression of HMHA1 C1-GAP and
GAP results in formation of protein aggregates suggesting that the
C-terminal tail-region is (partially) involved in proper localization
of the HMHA1 protein (Figure 2).
Because the actin cytoskeleton is under tight control of
RhoGTPases, we examined F-actin organization in cells express-
ing the different HMHA1 mutants. Neither the HMHA1 (FL) nor
the N-terminal construct affect F-Actin distribution (Figure 2;
upper two rows). However, constructs lacking the N-terminal BAR
domain (C1-GAPtail, C1-GAP, GAP, GAPtail) induce a dramatic
loss of F-actin (Figure 2; bottom 4 rows). In contrast to what we
observed for F-actin, the microtubule network remains unaffected
in cells expressing the different N-terminal deletion constructs
(Figure S1).
We analyzed possible effects on integrin-mediated adhesion by
recording focal adhesion distribution. Focal adhesions were
visualized by immunostaining for paxillin [27]. Whereas HMHA1
FL and N-term proteins did not affect the distribution of focal
HA1 Is a RhoGAP
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Figure 1. HMHA1 mutants and morphological effects. (A) Schematic overview of the organization of HMHA1 and of the different constructs
HA1 Is a RhoGAP
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adhesions, the C1-GAPtail, C1-GAP and GAPtail proteins
induced a marked loss of focal adhesions (Figure 3A). Paxillin-
positive structures were detected, albeit limited in number and
very small, mainly at the periphery of the cells, suggestive for a
defect in focal adhesion maturation. We therefore quantified focal
adhesion density based on paxillin staining and using image
analysis software (Figure 3B). These experiments indicate an
important role for HMHA1 in regulation of the actin cytoskeleton,
and in focal adhesion formation and distribution.
To confirm that cells expressing HMHA1 mutants lacking the
N-terminal region are less adhesive, we analyzed cell spreading by
ECIS (Electrical Cell-substrate Impedance Sensing) (Figure 4). In
these assays, cells are seeded on golden electrodes and the increase
in impedance, a measure for cell spreading, is recorded in real-
time [24]. HMHA1 FL (blue curve) or N-term (dark green curve)
did not significantly reduce cell spreading. However, cells
expressing HMHA1 C1-GAPtail (black), C1-GAP (light green),
and GAPtail (grey), showed a significant decrease in cell spreading.
HMHA1 GAP (magenta) slightly reduced cell spreading, but this
effect did not reach statistical significance (Figure 4).
These data suggest an important auto-inhibitory role for the
HMHA1 BAR domain comparable to what was shown for other
BAR-GAP proteins such as OPHN1 and GRAF1 [26,28]. The
HMHA1 GAP protein does not affect cell morphology or F-actin
distribution to the extent we observed for the HMHA1 GAPtail or
C1-GAP proteins, suggesting that either the C1 domain or the C-
terminus, which encodes a proline-rich region and a PDZ-binding
motif, is required for proper functioning of the HMHA1 RhoGAP
domain.
HMHA1 interacts and colocalizes with Rho-family
GTPases
Assuming that HMHA1 is putative RhoGAP, it is important to
realize that RhoGTPases, in particular Rac1, Cdc42, and RhoA,
are key regulators of actin reorganization. This knowledge led us
to analyze whether HMHA1 co-localizes with these RhoGTPases.
Interestingly, we found that HMHA1 co-localizes with Rac1 at
sites with high actin dynamics such as peripheral membrane ruffles
(Figure 5A). As GAP proteins are known to preferably bind to
active RhoGTPases, full-length HMHA1 was cotransfected with
mCherryRac1Q61L, a constitutively active Rac1 mutant. Similar
to what we observed for endogenous Rac1, HMHA1 co-localizes
with mCherryRac1Q61L in peripheral membrane ruffles
(Figure 5B). In addition, we analyzed co-localization of full-length
HMHA1 with the constitutively active mutants of Cdc42 (G12V;
Figure 5C) or RhoA (V14; Figure 5D). We observed a limited co-
localization of HMHA1 with Cdc42G12V and with RhoAV14
(Figure 5C, D; arrows).
To investigate this further for endogenous proteins, we
immunostained Jurkat T–cells with antibodies to HMHA1 and
Rac1 and analyzed the extent of colocalization by FACS analysis
combined with microscopic imaging. This was done using the
Image Stream technology that allows high-throughput, quantita-
tive image analysis of a large number of cells. The data in
Figure 6A show that endogenous HMHA1 and Rac1 show a high
level of colocalization and that both proteins also localize to
peripheral, F-actin-rich areas. The controls for the signal
selectivity in the different channels are in Figure S2. To investigate
if this localization is subject to regulation by extracellular stimuli,
we treated cells for several time-points with the chemokine
CXCL12. Subsequent FACS and image analysis (Figure 6B)
confirmed induction of F-actin dynamics after brief stimulation
with CXCL12 [29] and concomitant quantitative analysis of co-
localization of HMHA1 and Rac1 showed that there is a transient,
small increase in colocalization in response to CXCL12. However,
this transient effect is limited, likely due to the already high level of
colocalization of these two proteins. Both Rac1 and HMHA1
followed the CXCL12-induced actin dynamics and remained
localized to peripheral F-actin rich areas.
We next performed pull-down experiments with GST-Rac1
(used as a model for RhoGTPases) and determined the direct
interaction with bacterially purified HMHA1 C1-GAPtail. Our
data show that HMHA1 C1-GAPtail interacts with Rac1
preferably when Rac1 is loaded with GppNHp, a non-hydrolys-
able analog of GTP (Figure S3A). Previously, we identified several
proteins that regulate Rac1 activity, such as PACSIN2 and
caveolin, that interact with the Rac1 C-terminal hypervariable
domain [22,30]. To assess whether purified HMHA1 requires the
Rac1 C-terminal hypervariable domain for association, we
performed pull-down experiments with GST-fusions of Rac1WT
and Rac1DC, which lacks the hypervariable domain, loaded with
GDP or GppNHp. In contrast to PACSIN2 and caveolin,
HMHA1 C1-GAPtail binds to Rac1, independent of the C-
terminal hypervariable domain (Figure S3B). To test the specificity
of this interaction, we performed pull-down experiments with
GST-Rac1DC and GST-RhoADC loaded with either GDP or
GppNHp. We found that purified HMHA1 directly interacts with
both Rac1 and RhoA. In line with the above findings, HMHA1
preferably interacts with Rac1 and RhoA when they are in the
active, GppNHp-bound, conformation (Figure S3C).
In summary, HMHA1 colocalizes with RhoGTPases at sites of
high membrane dynamics and interacts directly with Rac1 and
RhoA.
Active Rac1 but not Cdc42 rescues the phenotype
induced by HMHA1 C1-GAPtail
Next we investigated whether ectopic expression of constitu-
tively active mutants of Rac1 (Rac1G12V and Q61L) or Cdc42
(G12V), that are unresponsive to GAP activity, could rescue the
phenotype induced by HMHA1 C1-GAPtail. Interestingly, both
mCherry-Rac1Q61L and G12V were able to bypass the effect
induced by HMHA1 C1-GAPtail (Figure 7A) in that cells
expressing both constitutively active Rac1 as well as HMHA1
C1-GAPtail show a more spread phenotype with less spine-like
protrusions as compared to the controls (mCherry-EV) (Figure 7A).
In contrast to active Rac1 mutants, Cdc42G12V did not rescue
cell morphology and spreading induced by the C1-GAPtail protein
(Figure 7B). We could not test whether constitutively active RhoA
(V14) rescued cell morphology or -spreading since both active
RhoA and HMHA1 C1-GAPtail induce contracted and loosely-
adherent cells. Likely as a result of this phenotype, we could not
detect any double-positive cells. Therefore, whether activation of
RhoA could rescue the dramatic phenotype induced by C1-
GAPtail remains unclear.
used in this study. (B) Morphology of HeLa cells, transfected as indicated, was analyzed by phase contrast microscopy. Cells expressing HMHA1 full-
length (FL), GAP, or N-term did not show any changes in morphology compared to control cells. HMHA1 C1-GAP, C1-GAPtail, and GAP-tail induce
dramatic changes in cell morphology. In addition, these cells are less adhesive than control cells. Scale bars, 50 mm.
doi:10.1371/journal.pone.0073962.g001
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Figure 2. Localization and effects on F-actin of HMHA1 and selected mutants. Intracellular localization of myc-tagged HMHA1 (and mutant
constructs) was studied by Confocal Laser Scanning Microscopy following expression in HeLa cells. Myc-tagged HMHA1 was detected by immunostaining for
themyc epitope in combinationwith detection of F-Actinwith phalloidin. Full-length HMHA1 (FL) as well as HMHA1N-term are partially localized atmembrane
ruffles as well as in the cytoplasm. For HMHA1 N-term localization at vesiculo-tubular structures is occasionally observed (arrows). Cells expressing FL or the N-
term constructs are morphologically similar to control cells and no effects are seen on F-Actin (upper two rows). HMHA1 constructs lacking the C-terminal tail
(GAP and C1-GAP) are partly mislocalized into protein aggregates. In cells expressing HMHA1 C1-GAP, C1-GAPtail, and GAPtail (marked with asteriks), F-Actin
distribution is altered and cell morphology is dramatically changed. Higher magnification images of the boxed area are included. Scale bars, 10 mm.
doi:10.1371/journal.pone.0073962.g002
HA1 Is a RhoGAP
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Figure 3. The HMHA1 GAP domain induces loss of focal adhesions. The effects of myc-tagged HMHA1 (and deletion constructs) on focal
adhesion distribution was studied by Confocal Laser Scanning Microscopy following expression in HeLa cells. Similar to the effects on F-Actin
distribution, cells expressing full-length HMHA1 (FL), N-term, or GAP (first, second and fifth rows) constructs show normal focal adhesion distribution
as detected using Paxillin immunostainings. Expression of HMHA1 C1-GAP, C1-GAPtail, or GAPtail (marked with asteriks) induces loss of focal
adhesions. In the merged images, HMHA1 constructs appear in red, paxillin in green and nuclei in blue. Higher magnification images of the boxed
area are included. Scale bars, 10 mm. (B) Mean +/2 SD of the average-per-cell paxillin staining intensity (10–20 cells per condition), quantified
following background subtraction, is indicated. Statistical differences compared to the Full-Length control are indicated by the respective p-values.
doi:10.1371/journal.pone.0073962.g003
HA1 Is a RhoGAP
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HMHA1 is a RhoGAP in vitro and its GAP function is
inhibited by the BAR domain
Next we analyzed the homology of the HMHA1 predicted
RhoGAP domain in comparison to p50RhoGAP, a prototypical
RhoGAP. Based on a similar BAR-GAP architecture we included
GRAF1 and OPHN1 in the analysis. Sequence alignment clearly
demonstrates high sequence homology of the HMHA1 RhoGAP
domain with the different human RhoGAPs p50RhoGAP,
GRAF1, and OPHN1, including a conserved Arg residue at
position 797 (Figure 8A; black bar).
Next, we generated a homology model of the HMHA1
RhoGAP domain based on the structure of the human
p50RhoGAP domain (Protein Data Bank (PDB) ID: 1tx4), the
latter being the top-scoring model predicted by the Phyre protein
structure prediction server [25]. Similar to other well-character-
ized RhoGAPs, including GRAF1 (in blue), the HMHA1
RhoGAP domain (in yellow) shows, with 9 a-helices, an
exclusively helical structure (Figure 8B). A hallmark of RhoGAPs
and other GAPs is the formation of a high-affinity complex with
the cognate inactive GDP-bound GTPase, only in the presence of
aluminium fluoride AlFx. This mimics the transition state of the
GTP hydrolysis (Rho?GDP?Pi?RhoGAP) [31]. The position of the
HMHA1 RhoGAP domain in complex with human RhoA bound
to GDP?AlFx (from RhoA?GDP?AlFx?p50RhoGAP; PDB ID:
1tx4), was defined through its superposition onto the p50RhoGAP
domain (Figure 8B). As described for other RhoGAPs, the
HMHA1 GAP domain interacts mainly with the P-loop and the
switch regions of RhoA (in light-green, Figure 8B). The invariant
Arg797 of the HMHA1 RhoGAP domain which may represent
the catalytic Arg residue (Arg finger) is orientated into the active
site of RhoA, close to AlFx and the nucleotide phosphates
(Figure 8B). The catalytic Arg residue neutralizes the developing
charge during the GTP hydrolysis and thus stabilizes the transition
state [31–33]. The highly conserved Gln residue in the switch II
region of Rho GTPases (Gln63 in RhoA, Gln61 in Rac1/Cdc42)
is required for an efficient GAP-catalyzed GTP hydrolysis as well,
since it coordinates the attacking water for the GTP cleavage [31–
33].
Our homology model indicates that HMHA1 contains the
structural requirements to function as a GAP protein and to
stimulate the GTP hydrolysis of Rho GTPases. To confirm this,
we analyzed GAP activity of HMHA1 in vitro using purified
proteins in a cell-free system. As a control, we measured GAP
activity of p50RhoGAP towards RhoA. As expected, when
combining p50RhoGAP with GTP-loaded RhoA, we observed
an increase in the release of inorganic phosphate, generated upon
GTP hydrolysis (Figure 8C; red bars). To analyze HMHA1 GAP
activity we used the purified C1-GAPtail protein. These experi-
ments showed that HMHA1 C1-GAPtail catalyzes GTP hydro-
lysis by Rac1, RhoA, and Cdc42 (Figure 8C; purple versus yellow
bars). HMHA1 C1-GAPtail did not catalyze GTP hydrolysis by
Ras (Figure 8C; right bar). These data indicate that HMHA1 acts
as a RhoGAP in vitro.
Several BAR-GAP proteins, including OPHN1 and GRAF1,
are autoinhibited by their BAR domain [26]. As HMHA1 is
structurally similar to these proteins and because dramatic effects
on actin dynamics and cell spreading are observed upon
expression of HMHA1 constructs lacking the BAR domain, we
tested whether the HMHA1 BAR domain auto-inhibits GAP
function towards RhoGTPases. We performed in vitro GAP assays
using purified RhoA and HMHA1 FL, as well as the N-terminal
construct including the BAR domain (N-term), and HMHA1 C1-
GAPtail. Similar to what has been shown for GRAF1 and
OPHN1, full-length HMHA1 as well as HMHA1 N-term showed
little or no GAP activity compared to HMHA1 C1-GAPtail which
lacks the N-terminal BAR domain (Figure 8D) suggesting that
HMHA1 is both structurally as well as functionally similar to
GRAF1 and OPHN1. In summary, these experiments show that
HMHA1 is a genuine RhoGAP and its GAP function is inhibited
by the N-terminal BAR domain.
HMHA1 regulates GTPase activity in vivo
Next we investigated whether HMHA1 regulates RhoGTPase
activity in vivo. First, we transfected HeLa cells with HMHA1 full-
length (FL), the N-terminal region (N-term), and C-terminal
constructs (C1-GAP and C1-GAPtail), that lack the BAR domain
and measured Rac1GTP loading. Similar to our in vitro results
(Figure 8C, D), full-length HMHA1 and the N-terminal region did
not significantly affect Rac1GTP loading. However, both C1-GAP
and C1-GAPtail drastically reduced Rac1GTP levels (Figure 9A)
indicating that HMHA1 functions in vivo similar as in vitro.
Next, we analyzed whether HMHA1 can regulate RhoA-GTP
loading in vivo using a RhoA G-LISA. As for Rac1GTP loading,
HMHA1 C1-GAPtail reduces levels of RhoA-GTP compared to
control cells (Figure 9B) indicating that in vivo HMHA1 can
regulate activity of both Rac1 and RhoA. As HMHA1 is not
endogenously expressed in HeLa cells we could not analyze Rac1-
or RhoA GTP loading when HMHA1 levels are reduced by short
interfering RNAs. As expression of HMHA1 is, under normal
Figure 4. The HMHA1 GAP domain negatively affects cell spreading. Cell spreading was measured by Electrical Cell-substrate Impedance
Sensing (ECIS) following seeding of 100.000 cells on fibronectin-coated electrodes. Left panel: A significant decrease in electrical resistance, as a
measure of cell spreading, was observed in HeLa cells expressing HMHA1 C1-GAPtail (black), C1-GAP (light green), and GAPtail (grey) compared to
control cells (red). Ectopic expression of HMHA1 full-length (blue), N-term (dark green), and GAP (magenta) did not affect cell spreading. Right panel:
Relative cell spreading at 60 minutes post-seeding. Data are mean values of three independent experiments. Error bars indicate SEM. ns, not
significant, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0073962.g004
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conditions, restricted to the hematopoietic system, we performed
both a CRIB pull-down assay and a RhoA G-LISA using Jurkat T
cells that express endogenous HMHA1. HMHA1 expression was
reduced via lentiviral shRNA to HMHA1. As expected, knock-
down of HMHA1 in Jurkat cells, using two shRNA constructs,
significantly increased Rac1GTP loading (Figure 9C). Interesting-
ly, in contrast to our results in HeLa cells, knock-down of HMHA1
does not significantly alter levels of RhoA-GTP in Jurkat cells
(Figure 9D) suggesting that in these cells HMHA1 may function
different than in HeLa cells. Although our in vitro data suggest that
HMHA1 regulates Cdc42, we did not observe altered levels of
Cdc42GTP in HeLa cells expressing HMHA1 C1-GAPtail (data
now shown).
Finally, we performed extensive analysis of chemotaxis of Jurkat
cells towards CXCL12. However, despite efficient reduction of
HMHA1 levels in Jurkat cells using lentiviral shRNA expression,
we observed no loss of chemotactic activity towards CXCL12.
This could be due to residual HMHA1 expression, which is
expressed to high levels in these cells (Figure 6) or to redundancy.
Loss of HMHA1 could be functionally compensated by related
RhoGAP proteins [18]. Similarly, loss of HMHA1 may increase
Rac1 activity, but this may not be relevant for chemotaxis in these
Figure 5. HMHA1 colocalizes with RhoGTPases. (A-D) Colocalization of myc-tagged HMHA1 with endogenous Rac1 (A), Rac1 Q61L (B), Cdc42
G12V (C) and RhoA V14 (D) was studied by Confocal Laser Scanning Microscopy. Myc-tagged HMHA1 and HMHA-tagged Cdc42 and RhoA were
detected by immunostaining in combination with detection of F-Actin. HMHA1 colocalized with endogenous Rac1 (A) and Rac1 Q61L (B) in
membrane ruffles (arrows). A partial colocalization of HMHA1 with Cdc42 G12V (C) and RhoA V14 (D) was observed (arrows) although less clear than
for Rac1. Higher magnification images of the boxed areas are included. Scale bars, 10 mm.
doi:10.1371/journal.pone.0073962.g005
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cells. This is not unprecedented, as it was shown for macrophages
that neither Rac1 nor Rac2 were required for cell migration [34].
Related GTPases, such as RhoG, could control cell migration
under these conditions [35]. To what extent such related GTPases
are targeted by HMHA1, or related GAP proteins, remains to be
investigated. Finally, it could be that the 2–2.5 fold-increased Rac1
activity in these cells (Figure 9C) neither impairs nor promotes
CXCL12-induced motility, since CXCL12 also stimulates Rac1
activity. Thus, defining the exact role of HMHA1 in motility of
lymphoid cells requires further analysis.
Discussion
The human minor H antigen HMHA-1 has been widely studied
in the context of human Stem Cell Transplantation (SCT) [36].
The minor H antigen HMHA-1 is a highly immunogenic
Figure 6. Visualization and flow cytometry analysis of endogenous HMHA1 using ImageStream. (A) Jurkat T-cells were fixed and
immunostained for endogenous HMHA1 and Rac1 and stained for F-actin and DNA. Left panel shows three examples of the distribution of HMHA1,
Rac1 and F-actin revealing colocalization of HMHA1 and Rac1 in F-actin rich areas. The nucleus (DNA) and cell morphology (phase image) are
included to show the integrity of the cell. Right panel shows intensity distribution of Rac1 (Y-axis) and HMHA1 (X-axis) signals, underscoring the fact
that most cells are double positive. (B) Jurkat cells were stimulated for the indicated time-points with 100 ng/ml CXCL12 and analyzed as in A. Two
examples of each condition are shown in the left panels. Changes in F-actin distribution in response to CXCL12 can be observed, in particular after 1
and 5 minutes. Right panels show the extent of colocalization (AU, arbitrary units) quantified by the image stream software. Ave, average
colocalization, n, number of cells.
doi:10.1371/journal.pone.0073962.g006
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nonameric peptide, encoded by the HMHA1 protein, and
presented to the immune system in an HLA-restricted fashion.
The minor H antigen HMHA-1 is expressed on all cells of the
hematopoietic system as well as on solid epithelial tumors of most
entities [4,5]. Based on its extraordinary expression patterns,
HMHA-1 is an ideal tumor target for Stem Cell based
immunotherapy [36]. So much attention had been focused on
the minor H antigen HMHA-1 in SCT, so little attention received
the cell biological role of its encoding gene, i.e. HMHA1.
Challenged by the expression and immunological characteristics
of the minor H antigen HMHA-1, we made a first attempt to
disclose the function of the HMHA1 gene that encodes the minor
H antigen HMHA1. Since our previous analysis of the primary
sequence of HMHA1 revealed that the protein encodes an N-
terminal BAR domain followed by a C1 and a RhoGAP domain
(Figure 1A), we focused on a potential role for HMHA1 in the
regulation of RhoGTPases [6].
RhoGTPase signaling is tightly controlled. Indeed, aberrant
signaling has often been linked to malignancies. GAPs terminate
RhoGTPase activity as they increase the intrinsic hydrolysis rate of
RhoGTPases [14]. Thus, RhoGAPs limit the duration and level of
GTPase signaling output. In the present study, we identified
HMHA1 as a novel RhoGAP. We found that HMHA1 shows
high sequence homology with known GAPs such as GRAF1 and
p50RhoGAP including the critical arginine finger in the catalytic
domain. Furthermore, the model we generated of the HMHA1
RhoGAP domain in complex with RhoA suggests that HMHA1 is
a RhoGAP. Our in vitro studies further supported this by showing
that HMHA1 has GAP activity towards the RhoGTPases, Rac1,
Cdc42, and RhoA. Moreover, the N-terminal BAR domain of
HMHA1 acts as an autoinhibitory module for GAP function as
full-length HMHA1 showed little GAP activity.
Based on these observations, HMHA1 can be positioned in a
subfamily of structurally related proteins that comprise an N-
terminal BAR domain followed by a RhoGAP domain[18]. Well-
studied proteins belonging to this subfamily of BAR-GAPs are
RICH1, OPHN1, SH3BP1, and GRAF1 [19–21,37]. Similar to
what we observed for HMHA1, the GAP function of these
proteins is auto-inhibited by their N-terminal BAR domain. For
OPHN1 and GRAF1, it was shown that the N-terminal BAR
domain can interact with the GAP domain, inhibiting its function
[26]. The mechanism by which the auto-inhibition in HMHA1 is
released remains to be investigated. This most likely involves
stimuli that target these BAR-GAPs to specific sites within the cell
or induce protein-protein interactions, unfolding the protein and
Figure 7. Constitutively active Rac1, but not Cdc42, rescues the altered cell morphology induced by HMHA1 C1-GAPtail. (A,B) Rescue
experiments with constitutively active Rac1 Q61L and G12V (A) or Cdc42 G12V (B), co-expressed with the HMHA1 C1-GAPtail protein were performed
in HeLa cells and analyzed by Confocal Laser Scanning Microscopy. Ectopically expressed proteins were visualized in combination with F-Actin. (A)
Constitutively active Rac1 Q61L (middle panels) and G12V (bottom panels) were able to (partially) rescue the phenotype induced by C1-GAPtail. As a
control, mCherry empty vector (EV; upper panels) was unable to rescue the phenotype. (B) Ectopic expression of constitutively active Cdc42 G12V did
not rescue the phenotype induced by C1-GAPtail. Scale bars, 10 mm.
doi:10.1371/journal.pone.0073962.g007
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releasing the GAP domain from BAR-domain-mediated inhibi-
tion.
By regulating RhoGTPase activity, HMHA1 regulates the actin
cytoskeleton. A C-terminal fragment of HMHA1, lacking the BAR
domain, had strong effects on cell morphology. Similar effects
were seen when mutants of SH3BP1 lacking its BAR domain were
expressed [19]. Cells expressing the HMHA1 mutants lacking the
N-terminus including the BAR domain show loss of F-Actin and
focal adhesions. Moreover, these cells spread less compared to
control cells. This phenotype is in line with our data showing that
HMHA1 acts as a RhoGAP, because RhoGTPase activity is
needed for proper cell adhesion and migration. Although we
observe in vitro GAP activity towards Rac1, Cdc42, and RhoA, it
could well be that in vivo, only a subset of these GTPases is subject
to control by HMHA1. The dramatic phenotype induced by the
HMHA1 C1-GAPtail construct was rescued by co-expressing
constitutively active Rac1 but not Cdc42 suggesting that HMHA1
primarily inactivates Rac1 in vivo. It is well established that the
small GTPase RhoA regulates stress fiber formation and focal
adhesion turnover [38]. Our data indicate that HMHA1 regulates
Figure 8. HMHA1 is a RhoGAP in vitro. (A) Sequence alignment of HMHA1 with the typical RhoGAP, p50RhoGAP, and the structurally-related
BAR-GAPs, GRAF1 and OPHN1. Green indicates two matching amino acids. Pink indicates three matching amino acids. Purple indicates four matching
amino acids. The arginine finger region is indicated with a black bar. (B) 3D model of the protein-protein complex between RhoA and the HMHA1
RhoGAP domain highlighting the catalytic residues (in sticks, colour coding as indicated; P-loop-Switch I-Switch II of RhoA in light green). The
homology model for the GAP domain of human HMHA1 is based on the structure of the human p50RhoGAP domain (PDB ID: 1tx4), using Phyre. The
position of the HMHA1 GAP domain in the complex with human RhoA (from RhoA?GDP?AlFx?p50RhoGAP; PDB ID: 1tx4) was obtained through its
overlay on the p50RhoGAP domain. The RhoGAP domain of GRAF1 from Gallus gallus (PDB ID: 1f7c) was superimposed onto the model of the HMHA1
GAP domain. (C) HMHA1 C1-GAPtail has in vitro GAP activity towards Rac1, Cdc42, and RhoA but not towards Ras (purple bars). p50RhoGAP was used
as a positive control (red bars). GTPases or HMHA1 only were used as a control and as a measure for intrinsic nucleotide hydrolysis (yellow bars). Data
are mean values of two independent experiments. Error bars indicate SD. (D) HMHA1 GAP activity is inhibited by the N-terminal BAR domain as full-
length HMHA1 has no GAP activity while C1-GAPtail, lacking the N-terminal region, shows GAP activity (purple bars). GTPases or HMHA1 only were
used as a control and as a measure for intrinsic hydrolysis (yellow bars). Data are mean values of two independent experiments. Error bars indicate SD.
doi:10.1371/journal.pone.0073962.g008
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Figure 9. HMHA1 regulates RhoGTPase activity in vivo. (A) HeLa cells were transfected as indicated. After 24 hours, a CRIB pull-down assay was
performed to measure levels of Rac1GTP. HMHA1 full-length (blue bar) and N-term (purple bar) do not significantly decrease Rac1GTP loading. The N-
terminal BAR domain auto-inhibits GAP function as HMHA1 C1-GAP (green bar) and C1-GAPtail (black bar), which lack the N-terminal BAR domain,
show a significant decrease in Rac1GTP loading compared to control cells (red bar). Data are mean values of five independent experiments. Error bars
indicate SEM. ns, not significant. * p,0.05, ** p,0.01. (B) HeLa cells were transfected as indicated. After 24 hours, a RhoA G-LISA (Cytoskeleton) was
used to measure levels of RhoA-GTP. HMHA1 full-length (red bar) and N-term (purple bar) did not significantly decrease RhoA-GTP loading. In
contrast, HMHA1 C1-GAPtail (pink bar), which lacks the N-terminal BAR domain, showed a significant decrease in RhoA-GTP loading compared to
control cells (red bar). Data are mean values of three independent experiments. Error bars indicate SEM. ns, not significant, * ,0.05, *** p,0.001. (C)
Jurkat cells were transduced with control (shC) or HMHA1 (shHMHA1 #2 or #3) short hairpin RNAs. After 72 hours, a CRIB pull-down assay was
performed to measure levels of Rac1GTP. Knock-down of HMHA1 significantly increases Rac1GTP loading compared to control cells. Data are mean
values of two (for shHMHA1#3) or three (for shHMHA1#2) independent experiments. Error bars indicate SD. * p,0.05. (D) Jurkat cells transduced as
indicated were lysed and RhoA-GTP levels were measured using a RhoA G-LISA. No significant differences in levels of RhoA-GTP loading were
observed between control cells and cells treated with shRNAs against HMHA1. Data are mean values of four measurements of two independent
experiments. Error bars indicate SD.
doi:10.1371/journal.pone.0073962.g009
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RhoA in vitro and in vivo although it was not possible to do the
rescue experiments to further substantiate this. Our in vivo activity
assays indicate that HMHA1 regulates Rac1GTP and RhoA-GTP
loading in HeLa cells. In contrast, in Jurkat cells, HMHA1 only
regulates the levels of Rac1GTP. These data further support the
notion that Rac1 and RhoA are in vivo targets of HMHA1.
Whether Cdc42 activity is regulated in vivo by HMHA1 requires
further investigation.
In many epithelial cancers, a change in tissue architecture called
epithelial-mesenchymal transition (EMT) occurs [39,40]. This
results in disruption of intercellular contacts and enhanced cell
motility leading to the release of single cells from the epithelial
tissue [40,41]. RhoGTPases, and in particular Rac1 and RhoA,
regulate epithelial cell-cell adhesion [42,43]. Being a regulator of
RhoGTPase output, abnormal HMHA1 expression in epithelial
cells could cause EMT, tumor cell invasion and metastasis.
Interestingly, although HMHA1 expression is restricted to the
hematopoietic system under normal conditions [4], in many
epithelial tumor cells HMHA1 gene expression was observed [5].
Moreover, minor H antigen HMHA-1-specific cytotoxic T cells
eradicate solid epithelial tumors in an in vivo animal model [8].
Whether expression of HMHA-1 is causal for the generation of
cancerous or metastasizing solid tumors remains to be investigat-
ed.
Understanding the role of HMHA1 in carcinogenesis might not
only be relevant from a cell biological point of view. The capability
of HMHA-1 specific immunotherapy to eradicate leukemia or
solid tumors strongly depends on whether HMHA-1 is expressed
on the earliest progenitor/stem cell from which the targeted
leukemia or solid tumor can repopulate. Our data demonstrate for
the first time that HMHA1 is not a coincidental "house keeping
gene", but plays an important role for functions crucial for
malignant cells. This may reduce the risk that HMHA1 protein
expression will be silenced by the cancer cells to evade the attack
by HMHA-1 specific CTLs. Remarkably, we could show that
HMHA1 expression remains intact in residual primary leukemia
cells even after successful treatment in our in vivo animal model
[7]. Additional studies are needed to show a similarly persistent
HMHA1 expression after HMHA-1 specific immunotherapy of
solid tumors. Moreover, the fact that cytoskeletal remodeling and
cell spreading are key functions of highly motile cells may well
explain the hematopoietic restriction of the HMHA1 under
normal conditions. Our previous studies showed that HMHA1 is
highly expressed particularly in lymphocytes and in hematopoietic
cells with phagocytic and/or antigen presenting capacity, i.e.
monocytes, langerhans cells or dendritic cells [44]. HMHA1
knockdown experiments are needed to understand the effect of
HMHA1 in inflammation.
In summary, we identified HMHA1 as a novel RhoGAP that
regulates the actin cytoskeleton and cell spreading. As endogenous
HMHA1 expression is normally limited to the hematopoietic
system, future studies should be aimed at defining the role of
HMHA1 in leukocytes in the context of actin remodeling, cell
migration, phagocytosis and antigen presentation. Since HMHA1
expression is detected in several epithelial cancer cells, future
studies should also address how HMHA1 is involved in the
transformation and invasive behavior of these epithelial cells.
Finally, HMHA1 might represent an excellent target for tumor
therapy because healthy epithelium does not express HMHA1.
The notion that HMHA1 indeed exerts GAP activity in vivo,
supports further research in this area.
Supporting Information
Figure S1 HMHA1 is not involved in microtubule
remodeling. The effects of myc-tagged HMHA1 (and deletion
constructs) on microtubule distribution was studied by Confocal
Laser Scanning Microscopy using HeLa cells. Myc-tagged
HMHA1 and microtubules were detected by immunostaining.
Although cell morphology is clearly affected, no major effects on
microtubule distribution are observed in HeLa cells expressing the
indicated HMHA1 constructs. Scale bars, 10 mm.
(TIF)
Figure S2 Immunostaining for endogenous HMHA1 and
Rac1. Jurkat cells were immunostained for endogenous HMHA1
and endogenous Rac1 and co-stained for F-actin using phalloidin.
Because HMHA1 and Rac1 and F-actin showed a high level of
colocalization (top panel), we confirmed lack of signal bleed-
through by staining with only HMHA1 (second panel), only Rac1
(third panel) or phalloidin only (bottom panel) followed by analysis
with identical settings as in Figure 6A. These analyses showed that
there is no cross talk between the different channels, further
confirming the colocalization analysis in Figure 6.
(TIF)
Figure S3 HMHA1 directly interacts with RhoGTPase.
(A) Pull-down experiments using GST-EV, and GST-Rac1 loaded
with GDP or GppNHP, a GTP analog that cannot be hydrolyzed,
show that HMHA1 C1-GAPtail directly interacts with Rac1
preferably when Rac1 is in the active conformation. Association of
purified C1-GAPtail was detected by immunoblotting (IB).
Ponceau staining indicates equal loading of GST input. (B) Pull-
down experiments with GST-Rac1 FL or DC, both loaded with
either GDP or GppNHp, show that HMHA1 C1-GAPtail directly
interacts with active Rac1, independent of the Rac1 hypervariable
C-terminus. Association of purified HMHA1 C1-GAPtail was
detected by immunoblotting. (C) Pull-down experiments using
GST-Rac1 or GST-RhoA, both loaded with either GDP or
GppNHp show that purified full-length HMHA1 directly interacts
with both active Rac1 and RhoA. Association of purified HMHA1
was detected by immunoblotting.
(TIF)
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